Clinical Trials Logo

Clinical Trial Summary

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04718844
Study type Interventional
Source Silence Therapeutics plc
Contact
Status Completed
Phase Phase 1
Start date April 14, 2021
Completion date May 23, 2023

See also
  Status Clinical Trial Phase
Completed NCT04364269 - Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia Phase 2
Completed NCT02993224 - Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet Phase 2
Withdrawn NCT04176653 - Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124 Phase 1